Latest Breaking News On - Schemic thromboembolism - Page 1 : comparemela.com

Germany: A recent study comparing apixaban and vitamin K antagonist (VKA) in atrial fibrillation (AF) patients on hemodialysis revealed no differences in safety or efficacy outcomes. AF patients on.

Safety study assessing oral anticoagulationVitamink antagonistsAtrial fibrillationEnd stage kidney diseaseRandomized controlled trial comparing apixabanVitamink antagonist phenprocoumonChronic hemodialysisAtrial fibrillationOn vitamink oral anticoagulantsSchemic thromboembolismEnd stage kidney disease